Ionis Pharmaceuticals, Inc. Costs and Expenses
Ionis Pharmaceuticals, Inc. (IONS) reported Costs and Expenses of $370.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. costs and expenses for the quarter ending 2026-06-30 was $370.24M, a 18.58% increase year-over-year.
- Ionis Pharmaceuticals, Inc. costs and expenses for the quarter ending 2026-03-31 was $363.51M, a 30.54% increase year-over-year.
- Ionis Pharmaceuticals, Inc. costs and expenses for the quarter ending 2025-12-31 was $417.79M, a 23.83% increase year-over-year.
- Ionis Pharmaceuticals, Inc. costs and expenses for the quarter ending 2025-09-30 was $316.90M, a 12.19% increase year-over-year.
- Ionis Pharmaceuticals, Inc. costs and expenses for fiscal 2025 was $1.33B, a 12.30% increase from fiscal 2024.
- Ionis Pharmaceuticals, Inc. costs and expenses for fiscal 2024 was $1.18B, a 3.40% increase from fiscal 2023.
- Ionis Pharmaceuticals, Inc. costs and expenses for fiscal 2023 was $1.14B, a 14.42% increase from fiscal 2022.
- Ionis Pharmaceuticals, Inc. costs and expenses for fiscal 2022 was $997.56M, a 18.67% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $370.24M 10-Q · filed 2026-07-29 | $733.76M 10-Q · filed 2026-07-29 | $1.15B derived: sum of 3 quarters · filed 2026-07-29 | $1.47B derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $363.51M 10-Q · filed 2026-04-29 | $781.30M derived: sum of 2 quarters · filed 2026-04-29 | $1.10B derived: sum of 3 quarters · filed 2026-04-29 | $1.41B derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $417.79M 10-K · filed 2026-02-26 | $734.69M derived: sum of 2 quarters · filed 2026-02-26 | $1.05B derived: sum of 3 quarters · filed 2026-07-29 | $1.33B 10-K · filed 2026-02-26 |
| 2025-09-30 | $316.90M 10-Q · filed 2025-10-29 | $629.13M derived: sum of 2 quarters · filed 2026-07-29 | $907.61M 10-Q · filed 2025-10-29 | $1.25B derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $312.23M 10-Q · filed 2026-07-29 | $590.71M 10-Q · filed 2026-07-29 | $928.10M derived: sum of 3 quarters · filed 2026-07-29 | $1.21B derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $278.47M 10-Q · filed 2026-04-29 | $615.87M derived: sum of 2 quarters · filed 2026-04-29 | $898.34M derived: sum of 3 quarters · filed 2026-04-29 | $1.19B derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $337.40M 10-K · filed 2026-02-26 | $619.87M derived: sum of 2 quarters · filed 2026-02-26 | $911.21M derived: sum of 3 quarters · filed 2026-02-26 | $1.18B 10-K · filed 2026-02-26 |
| 2024-09-30 | $282.47M 10-Q · filed 2025-10-29 | $573.81M derived: sum of 2 quarters · filed 2025-10-29 | $842.82M 10-Q · filed 2025-10-29 | $1.17B derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $291.34M 10-Q · filed 2025-07-30 | $560.35M 10-Q · filed 2025-07-30 | $890.98M derived: sum of 3 quarters · filed 2025-07-30 | $1.18B derived: sum of 4 quarters · filed 2025-07-30 |
| 2024-03-31 | $269.01M 10-Q · filed 2025-04-30 | $599.64M derived: sum of 2 quarters · filed 2025-04-30 | $887.11M derived: sum of 3 quarters · filed 2025-04-30 | $1.17B derived: sum of 4 quarters · filed 2025-04-30 |
| 2023-12-31 | $330.63M 10-K · filed 2025-02-19 | $618.10M derived: sum of 2 quarters · filed 2025-02-19 | $896.71M derived: sum of 3 quarters · filed 2025-02-19 | $1.14B 10-K · filed 2026-02-26 |
| 2023-09-30 | $287.47M 10-Q · filed 2024-11-06 | $566.08M derived: sum of 2 quarters · filed 2024-11-06 | $810.75M 10-Q · filed 2024-11-06 | $1.17B derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $278.61M 10-Q · filed 2024-08-01 | $523.28M 10-Q · filed 2024-08-01 | $883.19M derived: sum of 3 quarters · filed 2024-08-01 | $1.10B derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $244.67M 10-Q · filed 2024-05-07 | $604.58M derived: sum of 2 quarters · filed 2024-05-07 | $823.50M derived: sum of 3 quarters · filed 2024-05-07 | $1.04B derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $359.91M 10-K · filed 2024-02-21 | $578.83M derived: sum of 2 quarters · filed 2024-02-21 | $798.13M derived: sum of 3 quarters · filed 2024-02-21 | $997.56M 10-K · filed 2025-02-19 |
| 2022-09-30 | $218.92M 10-Q · filed 2023-11-02 | $438.23M derived: sum of 2 quarters · filed 2023-11-02 | $637.65M 10-Q · filed 2023-11-02 | $857.05M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $219.31M 10-Q · filed 2023-08-09 | $418.73M 10-Q · filed 2023-08-09 | $638.13M derived: sum of 3 quarters · filed 2023-08-09 | $857.07M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $199.42M 10-Q · filed 2023-05-03 | $418.83M derived: sum of 2 quarters · filed 2023-05-03 | $637.77M derived: sum of 3 quarters · filed 2023-05-03 | $836.49M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $219.40M 10-K · filed 2023-02-22 | $438.35M derived: sum of 2 quarters · filed 2023-02-22 | $637.06M derived: sum of 3 quarters · filed 2023-02-22 | $840.64M 10-K · filed 2024-02-21 |
| 2021-09-30 | $218.94M 10-Q · filed 2022-11-09 | $417.66M derived: sum of 2 quarters · filed 2022-11-09 | $621.24M 10-Q · filed 2022-11-09 | $934.18M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $198.72M 10-Q · filed 2022-08-09 | $402.30M 10-Q · filed 2022-08-09 | $715.24M derived: sum of 3 quarters · filed 2022-08-09 | $911.86M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $203.58M 10-Q · filed 2022-05-04 | $516.52M derived: sum of 2 quarters · filed 2022-05-04 | $713.14M derived: sum of 3 quarters · filed 2022-05-04 | $910.43M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $312.94M 10-K · filed 2022-02-25 | $509.56M derived: sum of 2 quarters · filed 2022-02-25 | $706.85M derived: sum of 3 quarters · filed 2022-02-25 | $901.35M 10-K · filed 2023-02-22 |
| 2020-09-30 | $196.62M 10-Q · filed 2021-11-03 | $393.91M derived: sum of 2 quarters · filed 2021-11-03 | $588.40M 10-Q · filed 2021-11-03 | $821.43M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $197.29M 10-Q · filed 2021-08-04 | $391.78M 10-Q · filed 2021-08-04 | $624.81M derived: sum of 3 quarters · filed 2021-08-04 | $790.18M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $194.49M 10-Q · filed 2021-05-05 | $427.52M derived: sum of 2 quarters · filed 2021-05-05 | $592.89M derived: sum of 3 quarters · filed 2021-05-05 | $775.53M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $233.03M 10-K · filed 2021-02-24 | $398.40M derived: sum of 2 quarters · filed 2021-02-24 | $581.04M derived: sum of 3 quarters · filed 2021-02-24 | $756.72M 10-K · filed 2022-02-25 |
| 2019-09-30 | $165.37M 10-Q · filed 2020-11-04 | $348.01M derived: sum of 2 quarters · filed 2020-11-04 | $523.69M 10-Q · filed 2020-11-04 | $705.02M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $182.64M 10-Q · filed 2020-08-05 | $358.32M 10-Q · filed 2020-08-05 | $539.65M derived: sum of 3 quarters · filed 2020-08-05 | $703.62M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $175.68M 10-Q · filed 2020-05-06 | $357.01M derived: sum of 2 quarters · filed 2020-05-06 | $520.98M derived: sum of 3 quarters · filed 2020-05-06 | $689.00M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $181.33M 10-K · filed 2020-03-02 | $345.30M derived: sum of 2 quarters · filed 2020-03-02 | $513.33M derived: sum of 3 quarters · filed 2020-03-02 | $661.05M 10-K · filed 2021-02-24 |
| 2018-09-30 | $163.97M 10-K · filed 2020-03-02 | $332.00M derived: sum of 2 quarters · filed 2020-03-02 | $479.72M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $168.03M 10-K · filed 2020-03-02 | $315.75M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $147.72M 10-K · filed 2020-03-02 | |||
| 2017-12-31 | $483.13M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |